Tarea para entregar impresa

1. Nombre: Ramìrez Corona Vrissa Vanessa. B-learning 56
Myriad Genetics Ending Patent Dispute on Breast Cancer Risk Testing
By ANDREW POLLACK JAN. 27, 2015
Myriad Genetics has essentially given up trying to stop other companies
from offering tests for increased risk of breast cancer, ending a dispute that
was the subject of a landmark Supreme Court ruling that human genes
cannot be patented.
The company has settled or is in the process of settling patent-
infringement lawsuits it filed against other companies that now offer such
testing, a Myriad spokesman said on Tuesday.
Myriad’s lucrative monopoly on testing for mutations in two genes linked to
an increased risk of breast and ovarian cancer ended in 2013, when the
Supreme Court ruled that human genes were not eligible for patents because
they were products of nature.
Numerous laboratories began offering tests, some for much less than the
roughly $4,000 Myriad charged for a complete analysis of the two genes,
known as BRCA1 and BRCA2.
Myriad sued many of those companies, saying they were infringing other
patent claims that had not been invalidated by the Supreme Court.
But last March, a federal district judge in Utah ruled against Myriad’s
request for a preliminary injunction against one competitor, Ambry Genetics.
Last month, the Court of Appeals for the Federal Circuit upheld the lower
court’s decision and ruled that those remaining claims were also ineligible for
patents.
After that ruling, “we decided it was in the best interest of the company to
settle these matters,” the Myriad spokesman, Ronald Rogers, said.
Settlements have been reached with LabCorp, Invitae and Pathway
Genomics. Mr. Rogers said Myriad was in talks with Ambry, Quest
Diagnostics, GeneDx and Counsyl.
In the settlements announced so far, the companies have agreed to
dismiss the claims and counterclaims against one another, and Myriad has
promised not to sue the companies on any remaining patents in the litigation.
Myriad is shifting from the BRCA gene test to a more comprehensive test
of 25 genes linked to cancer risk. It is also developing new types of tests to
reduce its reliance on the BRCA test.

2. Nombre: Ramìrez Corona Vrissa Vanessa. B-learning 56
1. Completa la siguiente tabla con palabras del texto aportando ejemplos
para todas las categorías gramaticales que recuerdes.
Línea Palabra(s) categoría gramatical significado
1 given verbo dado
1 essentially adverbio esencialmente
1 has verbo ha
3 was verbo haya
3 human adjetivo humanos
4 cannot verbo no pueden
5 company sustantivo compañía
6 filed verbo interpuso
6 against preposición contra
6 now adverbio ahora
6 offer verbo ofrecen
7 said verbo dijo
7 Tuesday adverbio martes
8 linked adjetivo relacionados
12 laboratories sustantivo laboratorios
9 ended verbo terminó
10 ruled verbo determinó
19 Last month adverbio El mes pasado
2. Identifica las siguientes categorías gramaticales marcando en el texto
con el color correspondiente.
10 Sustantivos
10 adjetivos
10 verbos
5 adverbios
5 preposiciones
3. Traduce las siguientes frases nominales.
ending a dispute poniendo fin a una controversia
other companies that now offer such Otras empresas que ahora ofrecen

3. Nombre: Ramìrez Corona Vrissa Vanessa. B-learning 56
testing estas pruebas
on testing for mutations en las pruebas para las mutaciones
that human genes were not eligible
for patents
que los genes humanos no eran objetos
de patentes
Numerous laboratories began
offering tests
Numerosos laboratorios comenzaron a
ofrecer pruebas
a complete analysis of the two genes,
known as BRCA1 and BRCA2
un análisis completo de los dos genes,
conocidos como BRCA1 y BRCA2
last March en marzo pasado
a federal district judge in Utah un juez federal de distrito en Utah
Last month El mes pasado
the settlements announced so far los asentamientos anunciados hasta el
momento
the companies have agreed las compañías han acordado
a more comprehensive una pruebas más completa
4. Copia del texto enunciados identificando las siguientes estructuras
debajo de cada título.
 SUJETO
 Myriad Genetics has essentially given up trying to stop other
companies from offering tests for increased risk of breast cáncer.
 The company has settled or is in the process of settling patent-
infringement lawsuits.
 the Supreme Court ruled that human genes were not eligible for
patents because they were products of nature.
 Myriad sued many of those companies.
 a federal district judge in Utah ruled against Myriad’s request for a
preliminary injunction against one competitor, Ambry Genetics.
 the Court of Appeals for the Federal Circuit upheld the lower court’s
decisión.

4. Nombre: Ramìrez Corona Vrissa Vanessa. B-learning 56
 the companies have agreed to dismiss the claims and counterclaims
against one another.
 Myriad is shifting from the BRCA gene test to a more comprehensive
test of 25 genes linked to cancer risk.
 COMPLEMENTO DIRECTO
 Myriad Genetics has essentially given up trying to stop other
companies from offering tests for increased risk of breast cáncer.
 the Supreme Court ruled that human genes were not eligible for
patents because they were products of nature.
 Myriad sued many of those companies.
 a federal district judge in Utah ruled against Myriad’s request for a
preliminary injunction against one competitor, Ambry Genetics.
 the Court of Appeals for the Federal Circuit upheld the lower court’s
decisión.
 COMPLEMENTO INDIRECTO (quien, para quien)
 Myriad Genetics has essentially given up trying to stop other
companies from offering tests for increased risk of breast cáncer.
 Myriad has promised not to sue the companies on any remaining
patents in the litigation.
 It is also developing new types of tests to reduce its reliance on the
BRCA test.
 COMPLEMENTO CIRCUNSTANCIAL (marca L, T, M, para identificar si
es de lugar, tiempo o modo).
o Tiempo. The company has settled or is in the process of settling
patent-infringement lawsuits it filed against other companies that now
offer such testing, a Myriad spokesman said on Tuesday.
o Tiempo. Myriad’s lucrative monopoly on testing for mutations in two
genes linked to an increased risk of breast and ovarian cancer ended
in 2013, when the Supreme Court ruled that human genes were not
eligible for patents because they were products of nature.
o Tiempo/Lugar. But last March, a federal district judge in Utah ruled
against Myriad’s request for a preliminary injunction against one
competitor, Ambry Genetics.

5. Nombre: Ramìrez Corona Vrissa Vanessa. B-learning 56
o Tiempo. Last month, the Court of Appeals for the Federal Circuit
upheld the lower court’s decision and ruled that those remaining
claims were also ineligible for patents.
o Tiempo. After that ruling, “we decided it was in the best interest of
the company to settle these matters,” the Myriad spokesman, Ronald
Rogers, said.
o Tiempo. In the settlements announced so far, the companies have
agreed to dismiss the claims and counterclaims against one another.
5. Mapa Mental. Elabora un mapa mental del texto.